Michel Delforge, MD, PhD, discusses the rationale for conducting the CARTITUDE-4 trial investigating cilta-cel in lenalidomide-refractory multiple myeloma.
Michel Delforge, MD, PhD
Advertisement
Articles by Michel Delforge, MD, PhD
Michel Delforge, MD, PhD, discusses the efficacy of cilta-cel in CARTITUDE-4 vs alternative approaches for lenalidomide-refractory myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
3
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5